C12N 2310/123
Hepatitis delta
C12N2310/123 (Hepatitis delta) appears on 79 US grants and 36 published applications in this corpus.
Search patents in C12N- Granted patents
- 79
- Published applications
- 36
- Assignees
- 29
- Inventors
- 82
- Latest grant
- 17 Oct 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 17 | 0 |
| 1998 | 17 | 0 |
| 1999 | 10 | 0 |
| 2000 | 7 | 0 |
| 2001 | 2 | 1 |
| 2002 | 9 | 3 |
| 2003 | 4 | 8 |
| 2004 | 1 | 1 |
| 2005 | 1 | 3 |
| 2006 | 3 | 2 |
| 2007 | 0 | 1 |
| 2008 | 0 | 2 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 2 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 1 | 2 |
| 2022 | 1 | 2 |
| 2023 | 1 | 1 |
| 2024 | 0 | 2 |
| 2025 | 0 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- CRISPR/Cas system and method for genome editing and modulating transcription17 Oct 2023US 11,788,088 B2The Board of Trustees of the University of Illinois
- Methods and compositions for directed genome editing7 Jun 2022US 11,352,623 B2Rewrite Therapeutics, Inc.
- Methods and compositions for directed genome editing7 Dec 2021US 11,193,123 B2Rewrite Therapeutics, Inc.
- Vector utilizing borna disease virus and use thereof14 Jun 2016US 9,365,865 B2Kyoto University
- Process for purifying VLPs10 Nov 2015US 9,181,531 B2Apse, Inc.
- Archaeal pyrrolysyl trna synthetases for orthogonal use4 Sep 2025US 2025/0277249 A1
- Ctrsd gate and performing co-transcriptional encoding20 Feb 2025US 2025/0059598 A1
- Rapid assembly of multiplex grna arrays24 Oct 2024US 2024/0355419 A1
- Crispr/cas system and method for genome editing and modulating transcription25 Jul 2024US 2024/0247262 A1The Board of Trustees of the University of Illinois
- Methods and Compositions for Directed Genome Editing9 Mar 2023US 2023/0076357 A1Intellia Therapeutics, Inc.
Most cited
By later US patents
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- RNA polymerase III-based expression of therapeutic RNAs154US 5,902,880 ARibozyme Pharmaceuticals, Inc. · 1999
- HIV nef targeted ribozymes131US 5,972,704 ARibozyme Pharmaceuticals, Inc. · 1999
- Therapeutic ribozyme compositions and expression vectors92US 5,225,347 AInnovir Laboratories, Inc. · 1993
- Deprotection of RNA with alkylamine72US 5,804,683 ARibozyme Pharmaceuticals, Inc. · 1998